Sorting and identification of side population cells in the human cervical cancer cell line HeLa

Cancer Cell International

Lihui Wei²  Weidong Yu³  Xiaoping Li²  Ning Liu¹  Lijun Zhao²  Chao Zhao²  Wenjuan Qi² 

[1] Haidian Maternal and Child Health Hospital, 33 Haidian South Road, Haidian District, Beijing 100080, China;Department of Gynecology and Obstetrics, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing 100044, China;Central Laboratory, Peking University People's Hospital, 11 Xizhimen South Street, Xicheng District, Beijing 100044, China

关键词: Radioresistance;    Chemoresistance;    Fluorescence-activated cell sorting;    Side population cells;    Cervical cancer cells;   

Others  :  792466
DOI  :  10.1186/1475-2867-14-3

 received in 2013-04-07, accepted in 2013-12-02,  发布年份 2014

【 摘 要 】

Background

Several reports have revealed that cancer stem cells (CSCs) exist in many types of solid tumors. Some studies have demonstrated that side population (SP) cells isolated from diverse cancer lines harbor cancer stem-like properties, but there are few reports examining the characteristic of SP cells in human cervical cancer. The aim of this study is 1) to find out a feasible way to detect the tumor stem-like cells in cervical cancer, and 2) to analyze the properties of the SP cells being sorted.

Methods

Isolated SP and non-SP cells from human cervical cancer cell line Hela by Hoechst 33342 dying method and flow cytometry analysis. Observing morphology of SP and non-SP cells. The expression of various biomarkers putatively related to cancer stem cells were investigated by immucytochemistry of SP and non-SP cells. We also analyzed cell cycle and cell apoptosis for sorted cells. The oncogenicity of the SP and non-SP cells were analyzed by tumor formation in nonobesediabeti- c/severe combined immune- deficient (NOD/SCID) mice. The drug-resistant and radiation-resistant index between SP, non-SP and Hela cells was estimated by MTS assay.

Results

The fraction of SP cells in Hela was approximately 1.07 ± 0.32%. SP cells were smaller and rounder in shape than non-SP cells, and mostly showed colony-like growth. Immunocytochemistry showed that stem cell makers (Oct3/4, CD133, BCRP) were highly expressed in SP cells. Moreover, the number of apoptotic cells among non-SP cells (17.6 ± 3.7%) was significantly higher compared with that among SP cells (4.4 ± 1.2%). The HE staining of in vivo grown tumors result from SP cells showed more poor differentiation, though no significant differences were shown between SP and non-SP cells in NOD/SCID mice tumorigenicity. Furthermore, SP cells demonstrated a higher degree of drug resistance against trichostatin A (TSA) compared with that of non-SP and Hela cells. SP cells were also found to be more resistant against radiotherapy.

Conclusions

SP cells possess some characteristics of CSCs, namely high proliferation ability, chemoresistance and radioresistance, which may be helpful to elucidate novel targets for effective clinical treatments of cervical cancer in the future.

【 授权许可】

   
2014 Qi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
• [2]Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
• [3]Goodell MABK, Paradis G, Conner AS, Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797-1806.
• [4]Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al.: A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid 1eukemia. Blood 2001, 98:1166-1173.
• [5]Setoguchi T, Taga T, Kondo T: Cancer stem cells persist in many cancer cell lines. Cell Cycle 2004, 3:414-415.
• [6]Chiba T, Kita K, Zheng YW, Yokosuka O, Iwama A, Nakauchi H: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
• [7]Hu L, McArthur C, Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010, 102:1276-1283.
• [8]Ho MM, Ng AV, Lam S, Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-4833.
• [9]Zhang SN, Huang FT, Huang YJ, Zhong W, Yu Z: Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells. Tumori 2010, 96:985-992.
• [10]Hadnagy A, Gaboury L, Beaulieu R, Balicki D: SP analysismay be used to identify cancer stem cell populations. Exp Cell Res 2006, 312:3701-3710.
• [11]Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998, 95:15665-15670.
• [12]Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, et al.: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.
• [13]Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
• [14]Kondo T, Setoguchi T, Taga T: Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-786.
• [15]Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, et al.: Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 2006, 24:506-513.
• [16]Hischmann-jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al.: A distinct"side population" of cells with high drug efflux capacity in huamn tumor cells. Proc Natl Acad Sci USA 2004, 101:142228-142233.
• [17]Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, et al.: Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009, 18:465-473.
• [18]Challen GA, Little MH: A Side Order of Stem Cells: The SP Phenotype. Stem Cells 2006, 24:3-12.
• [19]Yannamoto S, Kawasaki G, Yamada S, Yoshitomi I, Kawano T, Yonezawa H, et al.: Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral Oncol 2011, 47:855-860.
• [20]Schmuck R, Warneke V, Behrens HM, Simon E, Weichert W, Rocken C: Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 2011, 178:1792-1804.
• [21]Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP(ABCG2). Oncogene 2003, 22:7340-7358.
• [22]Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, et al.: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 2008, 29:2289-2297.
• [23]Moserle L, Ghisi M, Amadori A, Indraccolo S: Side population and cancer stem cell: therapeutic implications. Cancer letters 2010, 288:1-9.
• [24]Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
• [25]Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, et al.: Aldehyde dehydrogenase 1is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
• [26]Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, Van De Rijn M, et al.: The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Cancer Res 2005, 65:8118-8124.
• [27]Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al.: Identification of pancreatic cancer stem cells. Cancer Res 2007, 6:1030-1037.
• [28]Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al.: A distinct “side population” of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004, 101:14228-14233.
• [29]Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al.: Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006, 44:240-251.
• [30]Shi Y, Fu X, Hua Y, Han Y, Lu Y, Wang J: The side population in human lung cancer cell line NCI-H460 is enriched in stem-like cancer cells. PLoS One 2012, 7:1-8.
• [31]Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem cell-like side population cells in human Nasopharygeal carcinoma cell line. Cancer Res 2007, 67:3716-3724.
• [32]Pan J, Zhang Q, Wang Y, You M: 26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro. Plos One 2010, 5:1-9.
• [33]Platet N, Mayol J-F, Berger F, Herodin F, Wion D: Fluctuation of the SP/non-SP phenotype in the C6 glioma cell line. FEBS Letters 2007, 581:1435-1440.
• [34]Enokizono J, Kusuhara H, Sugiyama Y: Involvement of breast cancer resistance protein(BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect. Drug Metab Dispos 2007, 35:209-214.
• [35]Xia P, Gou WF, Wang JJ, Niu ZF, Chen S, Takano Y, et al.: Distinct radiosensitivity of lung carcinoma stem-like side population and main population cells. Cancer Biother Radiopharm 2013, 28:471-478.
• [36]Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, et al.: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells toradiotherapy. Mol Cancer Ther 2003, 2:353-360.
• [37]Zhang T, Cui GB, Zhang J, Zhang F, Zhou YA, Jiang T, et al.: Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation. Oncol Rep 2010, 24:1683-1689.
• [38]Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y: Akt inhibitor shows anticancer and radiosensitizing effects in maligant glioma cells by inducingautohagy. Int J Oncol 2007, 31:753-760.